Franck Lescure is Partner in charge of Life Sciences investments at Elaia Partners. Until 2018, Franck was Partner in charge of Life Sciences activities at Auriga Partners. Between 1990 and 1995, he has participated to the initial years of Genset, one of the first French biotech startups. Between 1997 and 2002, he joined the Air Liquide group in its healthcare subsidiary, followed by 2 years as member of the Venture Capital team of Crédit Lyonnais Private Equity. Franck Cumulates 28 years of experience in technology innovation, including 17 years in Capital Venture. He notably led investments in TxCell, Median or Erytech and he is currently on the board of directors of Amoeba, Enobraq, Fabentech, Flash Tx, Nosopharm, Pherecydes and Pylote.
Franck is an alumnus of the Ecole Normale Supérieure and of the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs.